,13,20 In fact, these findings even complement observations in the current literature regarding NAMPT-mediated venetoclax resistance, not only making the gene a source of acquired resistance present in relapsed and refractory AML LSCs,13 but also a prominent source of intrinsic ex vivo resistance to venetoclax. The gene discussed is NAMPT; the disease is acute myeloid leukemia.